Australia-wide medicinal cannabis study commenced

SYDNEY: Bod Australia Limited has commenced an Australia-wide, multi-clinic, open-label observational study into the effectiveness of its medicinal cannabis range, MediCabilis, for indications including anxiety disorders, insomnia and Post Traumatic Stress Disorder (PTSD).

The study aims to collect data from 500 patients who will be prescribed MediCabilis over a 12-month period with the aim of generating insights into the efficacy of the product on patients suffering from particular conditions.

The results will provide important data to support practitioners who are prescribing MediCabilis and assist Bod in modelling its planned future research and product development. The initiative will be run through approved study sites across Australia, with reputable partners including Cannabis Doctors Australia, CompassClinics, Cannabis Access Clinics and Tetra Health.

CEO Jo Patterson said: “We are confident that the outcomes from this extensive trial will provide important insights for medical practitioners into how MediCabilis can be best utilised for patients suffering from a number of chronic conditions and common, yet debilitating disorders.

“The need to find alternative solutions to treat a range of chronic health disorders is ever-present and we are hopeful that this trial will further demonstrate the effectiveness of MediCabilis in helping sufferers. The prevalence of these conditions amongst the global population is considerable -up to 33.7% of people are affected by an anxiety disorder during their life time with up to 30% not responding to regular treatment. Conditions such as chronic insomnia also have a significant impact on a sufferer’s health and can result in considerable healthcare costs.”

Bod’s Chief Scientific Officer Dr Adele Hosseini added: “One of the reasons doctors are hesitant to prescribe medicinal cannabis is because they do not feel there is sufficient high-quality evidence to support its safety and use. Bod is conducting this study to systematically collect validated, real-world data that will provide insight into how MediCabilis is being used and build the evidence base that will boost both practitioner and patient confidence and trust in the medicines.